Related references
Note: Only part of the references are listed.Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A2 mass in type 2 diabetes mellitus: Relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity
Alexander Constantinides et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2012)
Efficacy of Fenofibric Acid Plus Statins on Multiple Lipid Parameters and Its Safety in Women With Mixed Dyslipidemia
Anne C. Goldberg et al.
AMERICAN JOURNAL OF CARDIOLOGY (2011)
FIBRATE INDUCED RENAL INSUFFICIENCY
Carolien Beukhof et al.
European Journal of Internal Medicine (2011)
Pharmacoepidemiology Safety Study of Fibrate and Statin Concomitant Therapy
Cheryl Enger et al.
AMERICAN JOURNAL OF CARDIOLOGY (2010)
Efficacy and Safety of Fenofibric Acid Co-Administered with Low- or Moderate-Dose Statin in Patients with Mixed Dyslipidemia and Type 2 Diabetes Mellitus Results of a Pooled Subgroup Analysis from Three Randomized, Controlled, Double-Blind Trials
Peter H. Jones et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2010)
Efficacy and Safety of Rosuvastatin and Fenofibric Acid Combination Therapy versus Simvastatin Monotherapy in Patients with Hypercholesterolemia and Hypertriglyceridemia A Randomized, Double-Blind Study
Eli M. Roth et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2010)
Pitavastatin: A New HMG-CoA Reductase Inhibitor
Terri M. Wensel et al.
ANNALS OF PHARMACOTHERAPY (2010)
Efficacy and Safety of Rosuvastatin 5 mg in Combination with Fenofibric Acid 135 mg in Patients with Mixed Dyslipidemia - A Phase 3 Study
Eli M. Roth et al.
CARDIOVASCULAR DRUGS AND THERAPY (2010)
Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms
Reecha Sofat et al.
CIRCULATION (2010)
Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: A phase 3, randomized, controlled study
Syed M. Mohiuddin et al.
AMERICAN HEART JOURNAL (2009)
Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients
Giuseppe Derosa et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Dyslipidemia in type 2 diabetes mellitus
Arshag D. Mooradian
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2009)
Treatment of hyperlipidaemia with fenofibrate and related fibrates
Theodosios Filippatos et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Safety of aggressive lipid management
Michael H. Davidson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force
JM McKenney et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Microvascular endothelial function in subjects with Type 2 diabetes and the effect of lipid-lowering therapy
PG Fegan et al.
DIABETIC MEDICINE (2005)
Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia
KK Koh et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (The SAFARI Trial)
SM Grundy et al.
AMERICAN JOURNAL OF CARDIOLOGY (2005)
Reporting rate of Rhabdomyolysis with fenofibrate plus statin versus gemfibrozil plus any statin
PH Jones et al.
AMERICAN JOURNAL OF CARDIOLOGY (2005)
Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia
PN Durrington et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2004)
Comparison of fluvastatin plus fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: A 12-month, randomized, double-blind, controlled trial
G Derosa et al.
CLINICAL THERAPEUTICS (2004)
Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia
VG Athyros et al.
DIABETES CARE (2002)
Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study)
P Pauciullo et al.
ATHEROSCLEROSIS (2000)
Share Paper
